172 related articles for article (PubMed ID: 31213803)
1. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.
Mayer LD; Tardi P; Louie AC
Int J Nanomedicine; 2019; 14():3819-3830. PubMed ID: 31213803
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
Lancet JE; Cortes JE; Hogge DE; Tallman MS; Kovacsovics TJ; Damon LE; Komrokji R; Solomon SR; Kolitz JE; Cooper M; Yeager AM; Louie AC; Feldman EJ
Blood; 2014 May; 123(21):3239-46. PubMed ID: 24687088
[TBL] [Abstract][Full Text] [Related]
3. A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
Usuki K; Miyamoto T; Yamauchi T; Ando K; Ogawa Y; Onozawa M; Yamauchi T; Kiyoi H; Yokota A; Ikezoe T; Katsuoka Y; Takada S; Aotsuka N; Morita Y; Ishikawa T; Asada N; Ota S; Dohi A; Morimoto K; Imai S; Kishimoto U; Akashi K; Miyazaki Y;
Int J Hematol; 2024 Mar; ():. PubMed ID: 38532078
[TBL] [Abstract][Full Text] [Related]
4. Research on the preparation process of the cytarabine/daunorubicin dual-encapsulation liposome and its physicochemical properties and performances in vitro/vivo.
Liu B; Zhang J; Liu Z; Wang P; Zhang Y; He H; Yin T; Gou J; Tang X
Int J Pharm; 2023 Nov; 646():123500. PubMed ID: 37820944
[TBL] [Abstract][Full Text] [Related]
5. CPX-351 in
Andrews C; Pullarkat V; Recher C
Front Oncol; 2023; 13():1271722. PubMed ID: 38044999
[TBL] [Abstract][Full Text] [Related]
6. CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis.
Renga G; Nunzi E; Stincardini C; Pariano M; Puccetti M; Pieraccini G; Di Serio C; Fraziano M; Poerio N; Oikonomou V; Mosci P; Garaci E; Fianchi L; Pagano L; Romani L
Blood; 2024 Apr; 143(16):1628-1645. PubMed ID: 38227935
[TBL] [Abstract][Full Text] [Related]
7. Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro.
Fortin MC; LaCroix AS; Grammatopoulos TN; Tan L; Wang Q; Manca D
Sci Rep; 2023 Nov; 13(1):21054. PubMed ID: 38030645
[TBL] [Abstract][Full Text] [Related]
8. Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML.
Uy GL; Newell LF; Lin TL; Goldberg SL; Wieduwilt MJ; Ryan RJ; Faderl S; Lancet JE
Blood Adv; 2022 Sep; 6(17):4989-4993. PubMed ID: 35443022
[No Abstract] [Full Text] [Related]
9. Rationale and design of the Children's Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy.
Leger KJ; Robison N; Narayan HK; Smith AM; Tsega T; Chung J; Daniels A; Chen Z; Englefield V; Demissei BG; Lefebvre B; Morrow G; Dizon I; Gerbing RB; Pabari R; Getz KD; Aplenc R; Pollard JA; Chow EJ; Tang WHW; Border WL; Sachdeva R; Alonzo TA; Kolb EA; Cooper TM; Ky B
Front Cardiovasc Med; 2023; 10():1286241. PubMed ID: 38107263
[TBL] [Abstract][Full Text] [Related]
10. A new sequential conditioning regimen based on CPX- 351/Vyxeos ("Vyx-Seq") in patients with higher risk myelodysplastic syndromes.
Notarantonio AB; Roth-Guépin G; Bonmati C; Divoux M; Kicki C; Pagliuca S; Campidelli A; Rubio MT; D'Aveni-Piney M
Leuk Res; 2023 Dec; 135():107405. PubMed ID: 37864958
[No Abstract] [Full Text] [Related]
11. Uy GL, Newell LF, Lin TL, et al. Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML. Blood Adv. 2022;6(17):4989-4993.
Blood Adv; 2023 Jun; 7(12):2715-2717. PubMed ID: 37318935
[No Abstract] [Full Text] [Related]
12. Impact of different chemotherapy regimens on intestinal mucosal injury assessed with bedside ultrasound: a study in 213 AML patients.
Benedetti E; Traverso G; Pucci G; Morganti R; Bramanti E; Lippolis P; Susini MC; Mazzantini E; Giubbolini R; Mavilia F; Capochiani E; Neri E; Arena C; Cerri F; De Simone L; Valentini K; Stella SM; Ricchiuto V; Bruno B; Galimberti S
Front Oncol; 2023; 13():1272072. PubMed ID: 38023169
[TBL] [Abstract][Full Text] [Related]
13. Nanoscale Chemical Imaging of Individual, Chemotherapeutic Cytarabine-loaded Liposomal Nanocarriers.
Wieland K; Ramer G; Weiss VU; Allmaier G; Lendl B; Centrone A
Nano Res; 2019; 12():. PubMed ID: 31275527
[TBL] [Abstract][Full Text] [Related]
14. Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes.
Sasaki K
Lancet Haematol; 2023 Nov; 10(11):e872. PubMed ID: 37914477
[No Abstract] [Full Text] [Related]
15. CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.
Solomon SR; Powell BL; Koprivnikar J; Lai C; Male H; Michaelis LC; Newell LF; Sanford D; Jenkins J; Zelaya A; Coppola S; Faderl S; Walter RB
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473278
[TBL] [Abstract][Full Text] [Related]
16. Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes - Authors' reply.
Peterlin P; Fenaux P
Lancet Haematol; 2023 Nov; 10(11):e872-e873. PubMed ID: 37914476
[No Abstract] [Full Text] [Related]
17. CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases.
Ilyas R; McCullough K; Badar T; Patnaik MM; Alkhateeb H; Mangaonkar A; Pardanani A; Tefferi A; Gangat N
Blood Cancer J; 2023 Feb; 13(1):26. PubMed ID: 36797234
[No Abstract] [Full Text] [Related]
18. Alternating electric fields can improve chemotherapy treatment efficacy in blood cancer cell U937 (non-adherent cells).
Homami E; Goliaei B; Shariatpanahi SP; Habibi-Kelishomi Z
BMC Cancer; 2023 Sep; 23(1):861. PubMed ID: 37700230
[TBL] [Abstract][Full Text] [Related]
19. Liposomes: Biomedical Applications.
Kim EM; Jeong HJ
Chonnam Med J; 2021 Jan; 57(1):27-35. PubMed ID: 33537216
[TBL] [Abstract][Full Text] [Related]
20. CPX-351 (Vyxeos
Urbantat RM; Popper V; Menschel E; Pfeilstöcker M; Forjan E; Nader A; Sieghart CR; Keil F; Koller E
Clin Case Rep; 2021 Apr; 9(4):1933-1936. PubMed ID: 33936618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
